- Uses for whitening material of 4-(4-methylpiperazin-1-yl)-N-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)benzamide derivatives, or pharmaceutical acceptable salt thereof
-
The present invention relates to uses for a whitening material of a 4-(4-methylpiperazin-1-yl)-N-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)benzamide derivative, or a pharmaceutically acceptable salt thereof. A composition for whitening provided in
- -
-
Paragraph 0117; 0123-0125
(2020/11/04)
-
- Novel 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase)
-
The present invention relates to a 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivative or pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating maternal embryonic leu
- -
-
Paragraph 0231; 0232; 0233; 0234
(2017/08/19)
-
- Cu-Catalyzed Cyanation of Arylboronic Acids with Acetonitrile: A Dual Role of TEMPO
-
The cyanation of arylboronic acids by using acetonitrile as the "CN" source has been achieved under a Cu(cat.)/TEMPO system (TEMPO=2,2,6,6-tetramethylpiperidine N-oxide). The broad substrate scope includes a variety of electron-rich and electron-poor arylboronic acids, which react well to give the cyanated products in high to excellent yields. Mechanistic studies reveal that TEMPO-CH2CN, generated in situ, is an active cyanating reagent, and shows high reactivity for the formation of the CN- moiety. Moreover, TEMPO acts as a cheap oxidant to enable the reaction to be catalytic in copper. The cyanation of arylboronic acids by using acetonitrile as the "CN" source has been achieved under a Cu(cat.)/TEMPO system. Electron-rich and electron-poor arylboronic acids react well to give the cyanated products in high to excellent yields. Mechanistic studies reveal that TEMPO-CH2CN, generated in situ, is an active cyanating reagent. Moreover, TEMPO, a cheap oxidant, enables the reaction to be catalytic in copper (see scheme; TEMPO=2,2,6,6-tetramethylpiperidine N-oxide).
- Zhu, Yamin,Li, Linyi,Shen, Zengming
-
supporting information
p. 13246 - 13252
(2015/09/15)
-
- Derivatives of azaindoles or diazaindoles for treating pain
-
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.
- -
-
Paragraph 0184
(2014/02/15)
-
- DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN
-
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.
- -
-
Page/Page column 54
(2014/02/16)
-
- DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK
-
The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
- -
-
Page/Page column 53
(2014/02/16)
-
- Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
-
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
- -
-
Paragraph 0185
(2014/02/15)
-
- DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
-
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.
- -
-
Paragraph 0278; 0279; 0280
(2013/04/13)
-
- DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
-
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.
- -
-
Page/Page column 55
(2012/08/08)
-
- Trideuteriomethoxylation of aryl and heteroaryl halides
-
Direct access to trideuteriomethoxylated aromatic and heteroaromatic compounds has been developed. Various aryl and heteroaryl halides underwent d3-methoxylation under mild reaction conditions by using a catalyst system composed of the commercially available monodentate phosphane ligand tBuXPhos and Pd(OAc)2. Inexpensive CD3OD served as an efficient trideuteriomethoxylating agent. The simple and straightforward synthesis of labeled methyl (hetero)aryl ethers via palladium-catalyzed C-O cross-coupling reaction of (hetero)aryl halides with CD3OD was developed. The tBuXPhos ligand is used for the first time in ether synthesis. Copyright
- Dash, Pragyanditi,Janni, Manojkumar,Peruncheralathan, S.
-
supporting information
p. 4914 - 4917,4
(2012/12/12)
-
- Trideuteriomethoxylation of aryl and heteroaryl halides
-
Direct access to trideuteriomethoxylated aromatic and heteroaromatic compounds has been developed. Various aryl and heteroaryl halides underwent d3-methoxylation under mild reaction conditions by using a catalyst system composed of the commercially available monodentate phosphane ligand tBuXPhos and Pd(OAc)2. Inexpensive CD3OD served as an efficient trideuteriomethoxylating agent. The simple and straightforward synthesis of labeled methyl (hetero)aryl ethers via palladium-catalyzed C-O cross-coupling reaction of (hetero)aryl halides with CD3OD was developed. The tBuXPhos ligand is used for the first time in ether synthesis. Copyright
- Dash, Pragyanditi,Janni, Manojkumar,Peruncheralathan
-
supporting information
p. 4914 - 4917
(2013/01/14)
-
- Discovery of pyridine-2-ones as novel class of multidrug resistance (MDR) modulators: First structure-activity relationships
-
A novel facile synthesis led to pyridine-2-one target structures of which first series with varying substituents have been yielded and biologically characterized as novel multidrug resistance (MDR) modulators inhibiting P-glycoprotein (P-gp). Structure-ac
- Krawczyk, S?ren,Otto, Monika,Otto, Alexander,Coburger, Claudius,Krug, Martin,Seifert, Marianne,Tell, Volkmar,Molnár, Joséf,Higeroth, Andreas
-
experimental part
p. 6309 - 6315
(2012/01/13)
-
- 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE
-
A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
- -
-
Page/Page column 42
(2011/04/14)
-
- Novel Thienopyridines
-
A number of novel thienopyridines were prepared from the reaction of 1 with unsaturated haloalkanes, and by the reaction of the amino ketones 9 and 10 with DMF dimethylacetal or triethyl orthoformate.The synthesis of novel thieno and
- Dunn, A. D.,Norrie, R.
-
p. 483 - 486
(2007/10/02)
-
- Nucleophilic Displacements in Pyridine Rings
-
The reactions of halopyridines containing an electron withdrawing group (-CN, -CO2R, -COMe, -NO2) with sulphur nucleophiles is reported.
- Dunn, A. D.,Norrie, R.
-
-